 |
|
Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome
P. Michael Ho, MD, PhD;
Eric D. Peterson, MD, MPH;
Li Wang, MS;
David J. Magid, MD, MPH;
Stephan D. Fihn, MD, MPH;
Greg C. Larsen, MD;
Robert A. Jesse, MD, PhD;
John S. Rumsfeld, MD, PhD
JAMA. 2008;299(5):532-539.
Context It is unknown whether patients are at increased short-term risk for adverse events following clopidogrel cessation.
Objective To assess the rates of adverse events after stopping treatment with clopidogrel in a national sample of patients with acute coronary syndrome (ACS).
Design, Setting, and Patients Retrospective cohort study of 3137 patients with ACS discharged from 127 Veterans Affairs hospitals between October 1, 2003, and March 31, 2005, with posthospital treatment with clopidogrel.
Main Outcome Measure Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel.
Results Mean (SD) follow-up after stopping treatment with clopidogrel was 196 (152) days for medically treated patients with ACS without stents (n = 1568) and 203 (148) days for patients with ACS treated with percutaneous coronary intervention (PCI) (n = 1569). Among medically treated patients, mean (SD) duration of clopidogrel treatment was 302 (151) days and death or AMI occurred in 17.1% (n = 268) of patients, with 60.8% (n = 163) of events occurring during 0 to 90 days, 21.3% (n = 57) during 91 to 180 days, and 9.7% (n = 26) during 181 to 270 days after stopping treatment with clopidogrel. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping treatment with clopidogrel was associated with a significantly higher risk of adverse events (incidence rate ratio [IRR], 1.98; 95% confidence interval [CI], 1.46-2.69 vs the interval of 91-180 days). Similarly, among PCI-treated patients with ACS, mean (SD) duration of clopidogrel treatment was 278 (169) days and death or AMI occurred in 7.9% (n = 124) of patients, with 58.9% (n = 73) of events occurring during 0 to 90 days, 23.4% (n = 29) during 91 to 180 days, and 6.5% (n = 8) during 181 to 270 days after stopping clopidogrel treatment. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping clopidogrel treatment was associated with a significantly higher risk of adverse events (IRR, 1.82; 95% CI, 1.17-2.83).
Conclusions We observed a clustering of adverse events in the initial 90 days after stopping clopidogrel among both medically treated and PCI-treated patients with ACS, supporting the possibility of a clopidogrel rebound effect. Additional studies are needed to confirm the clustering of events after stopping clopidogrel, including associations with cardiovascular mortality and reasons for stopping clopidogrel, as well as to determine the mechanism of this phenomenon, and to identify strategies to reduce early events after clopidogrel cessation.
Author Affiliations: Denver VA Medical Center, Denver, Colorado (Drs Ho and Rumsfeld); University of Colorado Health Sciences Center, Denver (Drs Ho, Magid, and Rumsfeld); Duke Clinical Research Institute, Durham, North Carolina (Dr Peterson); VA Puget Sound Health Care System, Seattle, Washington (Ms Wang and Dr Fihn); Institute for Health Research, Kaiser Permanente of Colorado, Aurora (Drs Ho, Magid, and Rumsfeld); Portland VA Medical Center, Portland, Oregon (Dr Larsen); Richmond VA Medical Center, Richmond, Virginia (Dr Jesse); and Virginia Commonwealth University Health System, Richmond (Dr Jesse).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Dae Hyun Kim
JAMA. 2008;299(20):2388-2389.
EXTRACT
| FULL TEXT
Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Sandeep K. Goyal and Sujeeth R. Punnam
JAMA. 2008;299(20):2389.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Aprotinin reduces the antiplatelet effect of clopidogrel
Lindvall et al.
ICVTS 2009;9:178-181.
ABSTRACT
| FULL TEXT
Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
Leon et al.
J Am Coll Cardiol Intv 2009;2:504-512.
ABSTRACT
| FULL TEXT
Update on dual antiplatelet therapy for percutaneous coronary intervention
Prasad and Holmes
Heart 2009;95:861-865.
FULL TEXT
Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery
Blasco-Colmenares et al.
Arch Intern Med 2009;169:788-795.
ABSTRACT
| FULL TEXT
The Year in Epidemiology, Health Services Research, and Outcomes Research
Hlatky and Heidenreich
J Am Coll Cardiol 2009;53:1459-1466.
FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2009;53:1326-1337.
FULL TEXT
Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention.
Palmerini et al.
J Am Coll Cardiol 2009;53:1176-1181.
ABSTRACT
| FULL TEXT
Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
Angiolillo
Diabetes Care 2009;32:531-540.
FULL TEXT
Comparison of Drug-Eluting and Bare-Metal Stents for Stable Coronary Artery Disease
Horst et al.
J Am Coll Cardiol Intv 2009;2:321-328.
ABSTRACT
| FULL TEXT
The current state of antiplatelet therapy in acute coronary syndromes: The data and the real world
ALEXANDER
Cleveland Clinic Journal of Medicine 2009;76:S16-S23.
ABSTRACT
| FULL TEXT
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Juurlink et al.
CMAJ 2009;180:713-718.
ABSTRACT
| FULL TEXT
Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
Eisenberg et al.
Circulation 2009;119:1634-1642.
ABSTRACT
| FULL TEXT
Estimating the Impact of the Discontinuation of Medical Interventions on Health Outcomes
Weiss
Am J Epidemiol 2009;169:653-656.
ABSTRACT
| FULL TEXT
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
Ho et al.
JAMA 2009;301:937-944.
ABSTRACT
| FULL TEXT
P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
Scott et al.
The Annals of Pharmacotherapy 2009;43:64-76.
ABSTRACT
| FULL TEXT
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Chhatriwalla and Bhatt
Circ Cardiovasc Interv 2008;1:217-225.
FULL TEXT
Duration of antiplatelet therapy following intracoronary stenting: are changes needed?
Byrne and Kastrati
Eur Heart J Suppl 2008;10:I25-I29.
ABSTRACT
| FULL TEXT
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome
Giugliano and Braunwald
J Am Coll Cardiol 2008;52:1095-1103.
FULL TEXT
Progress Is Precarious
Head and Barash
Anesth. Analg. 2008;107:362-364.
FULL TEXT
Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Kim
JAMA 2008;299:2388-2389.
FULL TEXT
Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Goyal and Punnam
JAMA 2008;299:2389-2389.
FULL TEXT
All you need to read in the other general journals
BMJ 2008;336:354-355.
FULL TEXT
Clopidogrel Rebound?
Journal Watch Cardiology 2008;2008:1-1.
FULL TEXT
|
